The antidepressant effect of ketamine is not associated with changes in occipital amino acid neurotransmitter content as measured by [(1)H]-MRS.
about
Ketamine and other glutamate receptor modulators for depression in adultsA Randomized, placebo-controlled, crossover pilot trial of the oral selective NR2B antagonist MK-0657 in patients with treatment-resistant major depressive disorderRapid antidepressant effects: moving right alongReplication of ketamine's antidepressant efficacy in bipolar depression: a randomized controlled add-on trialTowards a glutamate hypothesis of depression: an emerging frontier of neuropsychopharmacology for mood disordersPreclinical pharmacology and pharmacokinetics of CERC-301, a GluN2B-selective N-methyl-D-aspartate receptor antagonistKetamine, Transcranial Magnetic Stimulation, and Depression Specific Yoga and Mindfulness Based Cognitive Therapy in Management of Treatment Resistant Depression: Review and Some Data on EfficacyTargeting the glutamatergic system to treat major depressive disorder: rationale and progress to dateKetamine for treatment-resistant unipolar depression: current evidenceKetamine as the prototype glutamatergic antidepressant: pharmacodynamic actions, and a systematic review and meta-analysis of efficacyA brief history of the development of antidepressant drugs: from monoamines to glutamateThe positive effect on ketamine as a priming adjuvant in antidepressant treatment.Glutamate and its receptors in the pathophysiology and treatment of major depressive disorderIn vivo effects of ketamine on glutamate-glutamine and gamma-aminobutyric acid in obsessive-compulsive disorder: Proof of conceptA pilot in vivo proton magnetic resonance spectroscopy study of amino acid neurotransmitter response to ketamine treatment of major depressive disorder.Inflammation Effects on Brain Glutamate in Depression: Mechanistic Considerations and Treatment Implications.A neurobiological hypothesis of treatment-resistant depression - mechanisms for selective serotonin reuptake inhibitor non-efficacy.Do the dissociative side effects of ketamine mediate its antidepressant effects?Glutamate receptor antagonists as fast-acting therapeutic alternatives for the treatment of depression: ketamine and other compounds.Decreased occipital cortical glutamate levels in response to successful cognitive-behavioral therapy and pharmacotherapy for major depressive disorder.A randomized trial of a low-trapping nonselective N-methyl-D-aspartate channel blocker in major depression.Ketamine and rapid-acting antidepressants: a window into a new neurobiology for mood disorder therapeuticsKetamine and other N-methyl-D-aspartate receptor antagonists in the treatment of depression: a perspective review.Clinical applications of hallucinogens: A review.Rapid antidepressant effect of ketamine in the electroconvulsive therapy setting.Randomized controlled crossover trial of ketamine in obsessive-compulsive disorder: proof-of-concept.Ketamine's antidepressant efficacy is extended for at least four weeks in subjects with a family history of an alcohol use disorder.Clinical predictors of ketamine response in treatment-resistant major depression.Ketamine as a promising prototype for a new generation of rapid-acting antidepressants.Glutamate metabolism in major depressive disorderCourse of improvement in depressive symptoms to a single intravenous infusion of ketamine vs add-on riluzole: results from a 4-week, double-blind, placebo-controlled studyAn investigation of amino-acid neurotransmitters as potential predictors of clinical improvement to ketamine in depressionSynaptic potentiation is critical for rapid antidepressant response to ketamine in treatment-resistant major depressionOff-label use of transmucosal ketamine as a rapid-acting antidepressant: a retrospective chart reviewKetamine for depression: where do we go from here?Relationship of ketamine's plasma metabolites with response, diagnosis, and side effects in major depression.Concomitant BDNF and sleep slow wave changes indicate ketamine-induced plasticity in major depressive disorderIncreased brain uptake and oxidation of acetate in heavy drinkers.Effects of Low-Dose and Very Low-Dose Ketamine among Patients with Major Depression: a Systematic Review and Meta-Analysis.Is there anything really novel on the antidepressant horizon?
P2860
Q24186746-BA66AA44-5F34-4A83-B94D-3E77F3EDC807Q24602988-D202186E-B463-4E8A-A995-E7EEC2C676FFQ24614410-4C058C07-0F22-48E2-B398-FE8D3F840D01Q24629398-D11CADA0-5FF5-4437-8322-A8A0D1D89783Q24632936-137BF623-70F1-4104-A3C9-C79366CFBC79Q26750021-FACF1BA1-A443-4B0C-8035-5B2503B61EA5Q26778251-39BFC6AA-14C2-407D-9C39-B63BC418B813Q27004490-15D242B1-4D68-4924-BB78-7D7EFC09C308Q27004508-F14BBA76-4B86-4EE7-9A66-C12D45316F8BQ27024227-C4EF97C4-ADBC-4441-946A-2BA0B5523504Q27028050-B8A679FD-1F36-42DA-9D84-031C1EC96274Q30408646-A655E359-2026-4195-B17C-FA85E57F14D2Q30711088-21CDD07D-7CC5-41F0-8B76-D90EE1AA7630Q30976220-F206E9F4-D177-410B-9D46-E3E3B2161F23Q30987882-35C1490D-D530-43D0-8553-133A8A4C3093Q31141746-AB355E06-F110-474E-B1BC-CBF0922AC453Q33658525-14108F01-0B61-40CE-8245-B80B17E693AEQ33787133-9425774E-DF11-4575-9242-5736510A9F10Q33874459-B40118F3-BF00-4D5C-8D74-979BA540E18BQ34181837-2586292C-A552-434E-8173-4BCC54992D7DQ34315128-4991D852-95B2-45C3-A343-1E8D3BC1692DQ34444632-B5422488-416F-4F97-B7BD-E069880CCCA7Q34475595-902FB4BC-2A56-4EF7-A74D-613E33789D7EQ34535259-358FEA9A-D416-4F52-8C79-6BFCA634DE25Q34640986-FE3BAE16-1D30-44E4-9428-DF3DB59B733EQ34653386-13142FD3-405E-4683-8837-14B5A94060FDQ35001345-6CEEA3A4-7F49-4D04-8CAB-9897174D183EQ35026766-10A9CAA9-BDCF-49A8-AC5C-87E8E7E24C49Q35547495-B6735EC5-162B-465F-AAC4-20B1C8AA3361Q35756139-6161B51C-B8E1-482F-9FF6-BA4BEAB8D641Q35892768-C1F4C184-385C-4866-A580-1723177ED0D5Q35928567-2DBC374E-61E9-461E-8E93-82587488991DQ36128314-8AC4BD9B-D318-44BB-8823-C5058F733EBFQ36176755-E964A009-9F02-4E4C-92A1-54422D6BC731Q36223372-7EAACFEF-93C8-4C67-8AAE-76AE320A39F2Q36233963-617236CD-6ED8-4503-AB08-991B8399B833Q36434538-A247C9B7-5348-4122-B696-C74272BADC59Q36733426-0E609F45-50A7-40A9-8DE4-7DDC5C495B24Q36852411-5246663B-ACC0-4017-9AFC-17FCB0AF3407Q36870889-222ED97F-113A-4606-A193-F5197E60476B
P2860
The antidepressant effect of ketamine is not associated with changes in occipital amino acid neurotransmitter content as measured by [(1)H]-MRS.
description
2011 nî lūn-bûn
@nan
2011 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
The antidepressant effect of k ...... itter content as measured by [
@nl
The antidepressant effect of k ...... ent as measured by [(1)H]-MRS.
@ast
The antidepressant effect of k ...... ent as measured by [(1)H]-MRS.
@en
type
label
The antidepressant effect of k ...... itter content as measured by [
@nl
The antidepressant effect of k ...... ent as measured by [(1)H]-MRS.
@ast
The antidepressant effect of k ...... ent as measured by [(1)H]-MRS.
@en
prefLabel
The antidepressant effect of k ...... itter content as measured by [
@nl
The antidepressant effect of k ...... ent as measured by [(1)H]-MRS.
@ast
The antidepressant effect of k ...... ent as measured by [(1)H]-MRS.
@en
P2093
P2860
P1433
P1476
The antidepressant effect of k ...... ent as measured by [(1)H]-MRS.
@en
P2093
Brian Pittman
Gerald W Valentine
Gerard Sanacora
Graeme F Mason
John H Krystal
June Watzl
Madonna Fasula
Rosane Gomez
P2860
P304
P356
10.1016/J.PSCYCHRESNS.2010.10.009
P407
P577
2011-01-12T00:00:00Z